Ignite Creation Date:
2024-05-06 @ 7:43 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02588404
Status:
NOT_YET_RECRUITING
Last Update Posted:
2016-07-28
First Post:
2015-10-26
Brief Title:
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sponsor:
Sir Mortimer B Davis - Jewish General Hospital
Organization:
Sir Mortimer B Davis - Jewish General Hospital
Study Overview
Official Title:
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Status:
NOT_YET_RECRUITING
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy
Detailed Description:
The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in prostate patients who have been treated with hormonal and radiation treatment after biochemical failure
Original biopsy slides of 65 patients will be collected and reviewed A tissue used to test and map DNA fragments will be constructed from patients who underwent radiation therapy RNA and DNA will be extracted from each slide This study if positive will establish the predictive value of TMPRSS2-ERG gene fusion in prostate cancer patients It can lead to believe that high-risk prostate cancer patients will benefit from a more aggressive treatment
An endpoint of this study is to evaluate the relation between the Gleason score and the TMPRSS2-ERG gene fusion Another is to evaluate the relation between the T-stage and TMPRSS2-ERG gene fusion
Original biopsy slides of 65 patients will be collected and reviewed A tissue used to test and map DNA fragments will be constructed from patients who underwent radiation therapy RNA and DNA will be extracted from each slide This study if positive will establish the predictive value of TMPRSS2-ERG gene fusion in prostate cancer patients It can lead to believe that high-risk prostate cancer patients will benefit from a more aggressive treatment
An endpoint of this study is to evaluate the relation between the Gleason score and the TMPRSS2-ERG gene fusion Another is to evaluate the relation between the T-stage and TMPRSS2-ERG gene fusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None